Zoetis Inc. (ZTS) is a leading pharmaceutical company that emphasizes the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products and services worldwide. The company’s last reported financial reports beat the analysts’ estimates. Its revenue of $2.39 billion surpassed the consensus estimate of $2.29 billion.
The company’s strong revenue growth was driven primarily by sales of companion animal products, up 18% year-over-year, drawn by monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela® for dogs, and Solensia® for cats. Further, Simparica Trio®, Apoquel®, and Cytopoint® also contributed to the growth during the quarter.
